Cargando…
The application of histone deacetylases inhibitors in glioblastoma
The epigenetic abnormality is generally accepted as the key to cancer initiation. Epigenetics that ensure the somatic inheritance of differentiated state is defined as a crucial factor influencing malignant phenotype without altering genotype. Histone modification is one such alteration playing an e...
Autores principales: | Chen, Rui, Zhang, Mengxian, Zhou, Yangmei, Guo, Wenjing, Yi, Ming, Zhang, Ziyan, Ding, Yanpeng, Wang, Yali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368699/ https://www.ncbi.nlm.nih.gov/pubmed/32682428 http://dx.doi.org/10.1186/s13046-020-01643-6 |
Ejemplares similares
-
Annexin‐1 is an oncogene in glioblastoma and causes tumour immune escape through the indirect upregulation of interleukin‐8
por: Chen, Rui, et al.
Publicado: (2022) -
Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
por: Meng, Wei, et al.
Publicado: (2018) -
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020) -
Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation
por: Rampazzo, Elena, et al.
Publicado: (2022)